Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2001

View Archived Issues

GlaxoSmithKline and First Genetic Trust to research adverse drug reactions

Enzo Biochem reports positive phase II data for hepatitis B treatment

ODAC meeting rescheduled for early December

Health Canada approves enhanced labeling for Copaxone

GSK, UCSF and MMV establish collaborative project

Foradil now cleared for use in COPD in the U.S.

First-in-class antibiotic introduced in major European market

Ibex enzyme therapeutics acquired by BioMarin

Introgen obtains exclusive worldwide license for tumor suppressor genes

Development of beraprost for intermittent claudication expected to be dropped

BioVex and AstraZeneca establish gene target validation collaboration

Cilomilast does not affect esophageal motility or gut transit times in man

Gliatech obtains disappointing results from MRI reevaluation of ADCON-L

Minodronate promising as parenteral or oral treatment of tumor-induced osteolysis

Approval of Viread recommended by FDA advisory committee

Combination therapy may have additional benefit in osteoporosis

Promising clinical data for LY-333334 discussed at ASBMR annual meeting

Vernalis makes substantial progress on development projects

Synthetic vitamin D analogue increases bone mass without hypercalcemia in osteoporosis

Experimental acute pancreatitis ameliorated by ET receptor blockade

Researcher at Northwestern discovers second ALS gene

Selective T-type calcium channel blockers discovered by Danish-American team

Aventis isolates new peptides which activate SARCA2

Use of MMP inhibitor compounds for preparation of diagnostic and therapeutic complexes

New antitumor compounds from Sugen interact with protein kinases

Japanese group identifies porphyrin compounds useful in photodynamic therapy of cancer

Lysophosphatidic acid receptor antagonists designed at Kirin Brewery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...